aTyr Pharma is cutting 60% of its workforce to fund a second phase 3 push for a lung disease drug after an initial failure. The report frames the move as a resource reallocation designed to preserve runway for the next clinical attempt. The company’s strategy signals how expensive late-stage trials can reshape small-cap biotech operations, particularly after program setbacks. By refinancing internal capacity through deep cost reductions, aTyr is attempting to avoid a long-term balance-sheet drag while advancing the same underlying clinical thesis. For investors and partners, the workforce reduction is a clear signal of commitment to relaunching phase 3 rather than shifting the pipeline toward earlier-stage trials.